|

Vascular Inflammation in Atherosclerosis - Whole Body Molecular PET/CT Imaging Using Folate Receptor β

RECRUITINGN/ASponsored by Turku University Hospital
Actively Recruiting
PhaseN/A
SponsorTurku University Hospital
Started2026-10-01
Est. completion2027-12
Eligibility
Age50 Years – 80 Years
Healthy vol.Accepted

Summary

This study investigates inflammation in the blood vessels of people with coronary artery disease (CAD) or a recent myocardial infarction. Inflammation plays an important role in the development and progression of atherosclerosis, but there is currently no established clinical imaging method for detecting inflammation in atherosclerotic plaques throughout the body. The study uses a new PET imaging tracer called 18F-AlF-NOTA-Folate. The tracer is designed to bind to folate receptor beta (FR-β), a marker found on activated macrophages, which are immune cells involved in inflammation. The aim is to determine whether PET imaging with this tracer can detect and measure inflammation in atherosclerotic plaques. Approximately 90 patients will participate. One group will include patients with suspected or stable coronary artery disease who are undergoing coronary CT angiography and PET imaging as part of their clinical assessment. A second, smaller group will include patients who have recently had a myocardial infarction. Participants will undergo PET and CT imaging and provide blood samples. The imaging will examine the coronary arteries and other major arteries, including the carotid arteries, aorta and iliac arteries. The study will also investigate blood flow in the heart and other organs and examine the relationship between vascular inflammation, atherosclerotic plaque characteristics and markers of inflammation in the blood. The study is not testing a treatment for coronary artery disease. The folate tracer is administered only for imaging purposes. Participants will be followed through hospital and registry records for up to five years to investigate whether imaging findings are associated with later cardiovascular events. The study may provide new information about how inflammation is distributed in atherosclerosis and whether FR-β-targeted PET imaging could be useful for detecting and studying vascular inflammation in patients with cardiovascular disease.

Eligibility

Age: 50 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

Group A:

\- Patients aged 50-80 years with suspected coronary artery disease who have undergone coronary CT angiography and are referred for cardiac 15O-water PET perfusion imaging based on suspected obstructive coronary artery disease.

Group B:

\- Patients aged 50-80 years with a recent myocardial infarction.

For both group A and B:

\- Written informed consent.

Exclusion Criteria:

* unstable angina symptoms
* previous myocardial infarction (Group A)
* previous coronary artery bypass grafting or previous percutaneous coronary intervention
* severe pulmonary disease
* severe symptomatic asthma
* severe valvular disease
* uncontrolled hypertension (\>180/110 mmHg)
* severe hypotension (systolic blood pressure \<100 mmHg)
* severe renal failure
* pregnancy
* age \<50 or \>80 years
* second- or third-degree atrioventricular block or sick sinus syndrome without a pacemaker
* allergy to X-ray contrast agents
* known inflammatory disease, including rheumatic or autoimmune disease, sarcoidosis, or myocarditis
* known infection
* use of anti-inflammatory medication or folate antagonists such as corticosteroids or methotrexate; known cancer.

Conditions3

AtherosclerosesHeart DiseaseInflammation

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.